Summary The purpose of this study was to compare alpha-L-fucosidase and alpha-fetoprotein as serum markers of hepatocellular carcinoma in 72 southern African blacks with this tumour and 64 matched patients with benign hepatic diseases which might be mistaken clinically for hepatocellular carcinoma. Alpha-Lfucosidase activity was assayed using p-nitrophenyl-L-fucopyranoside (pNpf) as a substrate and alphafetoprotein concentrations were measured by radioimmunoassay. Serum alpha-L-fucosidase activity in the patients with hepatocellular carcinoma (mean 1,268, s.e.m. + 83.7, median 1,150 and range 38-3,698 nmol pNpfml -h -1) was significantly higher than that in the matched controls (mean 798, s.e.m. +65.8, median 648 and range 273-3,825nmol pNpfml-l h-1) (P=0.0001). However, alpha-L-fucosidase was both less sensitive (75 versus 87%) and less specific (70 versus 87%) than alpha-fetoprotein as a serum marker of hepatocellular carcinoma. When, in an endeavour to eliminate false-positive results, the diagnostic cut-off level for alpha-L-fucosidase was increased to 1,500nmol pNpfml-' h-1 and for alpha-fetoprotein to 400ngml-1, the sensitivity of alpha-L-fucosidase fell to 21% whereas that of alpha-fetoprotein remained satisfactory at 78%. If the two markers were used together, the number of false-negative alpha-fetoprotein results was reduced from 13 to 5.5%. We conclude that alpha-L-fucosidase is less useful than alphafetoprotein as a single marker of hepatocellular carcinoma in southern African blacks. However, the two markers can profitably be used together.
The lysosomal hydrolase, alpha-L-fucosidase (alpha-Lfucoside fucohydrolase; 3.2.1.51; AFU), is present in many mammalian tissues where it degrades fucose-containing glycoconjugates. A number of isomers of the enzyme have been identified in human tissues, including two hepatic forms (Robinson & Thorpe, 1973) . The clinical importance of AFU is indicated by the occurrence, albeit rare, of a deficiency state that results in a neurovisceral storage disease known as fucosidosis (Durand et al., 1969) , and by the observation that women with low serum activity of the enzyme may be prone to ovarian carcinoma (Lynch et al., 1985) . Raised serum concentrations of AFU have been described in patients with a variety of benign diseases, including diabetes, hyperthyroidism, toxic oil syndrome and, of particular relevance to the present study, cirrhosis, alcoholic hepatitis and acute viral hepatitis (Reglero et al., 1980; Calvo et al., 1982; Guillou et al., 1982; Cabezas-Delamore et al., 1983; Deugnier et al., 1984; DiCioccio et al., 1985) . Increased AFU activity has also been reported in association with carcinoma of the lung, breast, stomach, ovary and uterus and, more recently, with hepatocellular carcinoma (HCC) (Reglero et al., 1980; Calvo et al., 1982; Deugnier et al., 1984; DiCioccio et al., 1985) . Deugnier and his colleagues (1984) found serum levels of AFU to be raised in European patients with HCC more often than serum concentrations of alpha-fetoprotein (AFP), although they cautioned that studies in larger numbers of patients were needed before liver cancer specificity could be assigned to AFU. However, DiCioccio et al. (1985) were later unable to distinguish between HCC and cirrhosis in North American patients on the basis of serum AFU concentrations. The purpose of this study was to compare AFU and AFP as serum markers of HCC in southern African blacks, a population that has both a high incidence of the tumour and in which AFP is a more useful tumour marker than it is in 'western' populations with a low incidence of HCC (Kew & Newberne, 1982 Serum AFU activity was assayed using a method similar to that described by Troost et al. (1976) . A mixture of 0.25 ml of 4mM p-nitrophenyl-L-fucopyranoside (pNpf) (Sigma Chemical Co, St Louis, MO), 0.5 ml 0.2 M sodium acetate buffer (pH 5.5) and 0.125ml serum was made up to a final volume of 1 ml with distilled water. The mixture was incubated at 37°C for 60 min, after which the reaction was inhibited by the addition of 0.2 M glycine NaCl (brought to a pH of 10.7 with sodium hydroxide). Duplicate assay mixtures and control assays lacking serum or substrate (pNpf) made up to a total volume of 1 ml were incubated at 37°C for 1 h. Absorbance was measured at 400 nm and the enzymatic activity expressed in nmol pNpfml-I h -. The resulting absorbance spectrophotometric curve was linear to an absorbance of 0.8. Samples falling in the range higher than this were diluted further.
Serum AFP concentrations were measured in the same patients using radioimmunoassay (Amersham International, Amersham, UK). The effects of collection and storage on serum AFU activity were determined by an analysis of variance and the significance level was corrected according to the Bonferoni adjustment (the reason for using this adjustment was that simultaneous tests were done, necessitating that the level of significance be adjusted to provide for these comparisons, i.e. the test level is divided by the number of comparisons being made) (Rupert & Miller, 1981) . The variables tested were fasting compared with non-fasting (in 12 caucasian subjects), duration of storage at -20CC (less than 12h compared with greater than 24 h; 1 day compared with 1, 4 and 8 weeks), and storage at 4°C and -20°C (in 28 caucasian subjects). The means of the AFU values in the fasting and non-fasting sera were corrected for storage time. Student's t test was applied to compare the AFU concentrations in the caucasian Br. J. Cancer (1989) , 59, [417] [418] [419] [420] and black controls. The sera from the black and caucasian subjects were stored under identical conditions. Receiver operating characteristic (ROC) curves were constructed for both AFU and AFP, and they were compared using Student's t test. ROC curves are plots of the percentage truepositives against the percentage false-positives for multiple thresholds (Herman et al., 1988 Effect of method and duration of storage Significantly higher serum AFU concentrations were found in sera which had been stored for longer than 24 h in comparison with sera stored for less than 12 h (Table I) . However, no significant differences existed when samples were stored from 24 h up to 8 weeks (Table I Figure 1 (0.9191, s.e.m. + 0.0262) was greater than that for AFU (0.7749, s.e.m. + 0.0398) (P=0.0013), confirming that AFP is a superior marker for HCC. The ideal cut-off point for a diagnostic value of AFU was determined by random selection of multiple points from the ROC curve (Table III) . The point considered best (820 nmol pNpf ml -'h-) was, coincidentally, two standard deviations above the mean value. Figure 2 illustrates the distribution of serum AFU activity in the patients at this cut-off level. At this concentration AFU has a sensitivity in southern African blacks of 75% and a specificity of 70%. This compares with a sensitivity and a specificity of 87% for AFP at a level of >20ngml-1 (Table II) . At the higher diagnostic cut-off level for AFP of 400 ng ml-1, the specificity is 96% and the sensitivity remains high at 78%. However, when the diagnostic cut-off level for AFU was increased to achieve a similar specificity (95%), its sensitivity fell to 21 % (Table III) .
Discussion
Normal serum AFU activity ranges between 350 and 660 nmol pNpfml -h - (Turner et al., 1975; Troost et al., 1976; Deugnier et al., 1984) . Although not specified, these values were probably established in caucasian subjects. Not unexpectedly, we found caucasian subjects living in South Africa to have similar serum concentrations. Of considerable interest was our finding of appreciably higher serum levels of AFU in apparently healthy blacks. This has not previously been described, and may possibly be explained by racial differences in the distribution of AFU phenotypes (Turner et al., 1975 (Turner et al., 1975) . Although AFP remains the 'gold standard' against which other serum markers of HCC must be compared, falsenegative results may occur in 20-30% of patients in regions with a low incidence of the tumour, and false-positive results may be seen in patients with undifferentiated teratocarcinomas or embryonal cell carcinomas of the testis or ovary, tumours of entodermal origin, and in various forms of acute and chronic benign hepatic disease (Kew & Newberne, 1982) . The search for an ideal serum marker for HCC therefore continues. Deugnier et al. (1984) found raised serum AFU activity to be both more sensitive and more specific than an elevated serum AFP concentration as a marker for HCC in French patients. In the present study involving black patients with HCC or various benign hepatic diseases which might be mistaken clinically for HCC, the sensitivity and specificity of AFU proved to be the same as that reported by Deugnier et al. (1984) . However, AFP is known to be more sensitive in blacks than in caucasians with HCC (Kew & Newberne, 1982) , and this explains our finding that AFP was the better marker in a black population. Both the study of Deugnier et al. (1984) and our investigation have shown that the two markers can profitably be used in conjunction. If this was done, the percentage of false-negative AFP results in black patients was reduced from 13 to 5.5 per cent.
If financial constraints are a consideration, AFU is both cheaper to measure than AFP (less than US$1 per test compared with more than US$2 per test) and has a lesser initial outlay for laboratory equipment.
The reason for the increase in serum activity of AFU in HCC is not known. The most likely explanation is that the raised serum concentrations result from an increased synthesis of proteins by the tumour with consequent increased fucose turnover (Vischer & Reutter, 1978; Holmes & Hakamori, 1982) . 
